Creative medical technology holdings inc. announces fda authorization for groundbreaking type 1 diabetes prevention therapy under expanded access

Phoenix--(business wire)--creative medical technology holdings, inc., (nasdaq:celz), a leader in biotech innovation, today announced a major stride in combating type 1 diabetes mellitus (t1d). the company has secured fda authorization for an expanded access therapy using celz-201, a pioneering cell-based program in managing abnormal glucose tolerance and preventing t1d in high-risk individuals. this groundbreaking therapy uses celz-201 to potentially prevent t1d onset and is believed to be a fi.
CELZ Ratings Summary
CELZ Quant Ranking